Main Industry
Biotechnology
Main Product/Service
New drug development, custom chemical synthesis, pharmacological activity testing, analytical testing, and development of novel therapeutics targeting irritable bowel syndrome (IBS)-related chronic abdominal pain.
Founded Year
2025
Unified Business No.
60713647
Status
Active
Total Paid-in
Capital
10,550,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LYNTONIX is a biotech startup spun out from a National Taiwan University research team. It focuses on developing non-addictive treatments for chronic pain, particularly irritable bowel syndrome (IBS)-related abdominal pain. Its lead candidate LTX-568 targets a newly discovered pain mechanism and has completed preclinical studies, with plans for IND-enabling studies and clinical trials in the coming years.
